Epigenomics Raises $6.6M in Share Placement | GenomeWeb

NEW YORK (GenomeWeb News) - Epigenomics said today that it has placed 2,671,088 new shares at an issue price of €1.94 per share, raising gross proceeds of €5.18 million ($6.6 million).

A subsidiary of BB Medtech and funds managed by Abingworth subscribed for all the new shares. The transaction will double the BB Medtech group's stake in Epigenomics to about 14.9 percent from about 7.4 percent, making it the second largest shareholder in the firm after Federated Investors. Funds managed by Abingworth will own about 11.1 percent of the company's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.